研報掘金丨國信證券:賽力斯作為豪華車領域標杆車企,應有一定估值溢價,維持“優於大市”評級
國信證券研報指出,賽力斯(601127.SH)業務在2024年迎來爆發期,第三季度,依然能保持業務的高速增長。前三季度營收累計1066.27億元,同比增長539.2%;第三季度營收415.82億元,環比持續提升。公司在2024年一季度實現了季度利潤的扭虧為盈,前三季度,歸母淨利潤達到了40.38億;第三季度歸母淨利潤24.13億,環比增長71.7%。公司產品是目前國內豪華車領域標杆產品,豪華車賽道兼具高護城河和高毛利,公司作為豪華車領域標杆車企,應有一定的估值溢價。給予公司2025年19-21倍PE,對應股價130.56-144.30元,維持“優於大市”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.